Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

RESI Europe Partnering Opens March 2: Secure Investor Meetings Early and Bring a Complimentary Second Attendee

24 Feb

By Greg Mannix, VP, EMEA Business Development, LSN

As RESI Europe 2026 approaches, one of the most important milestones is just ahead. On March 2, the partnering platform officially opens, giving registered attendees the opportunity to begin requesting and scheduling meetings with investors, strategic partners, and fellow innovators across the global life science ecosystem.

Below are two key updates to plan around.

Partnering Opens March 2: Secure Meetings Early

Partnering is the foundation of every RESI conference. From the moment the platform opens, companies can review attendee profiles, identify aligned investors and strategic partners, and begin building a focused meeting schedule.

The earlier you register and enter the platform, the more time you can:

  • Refine your profile and messaging
  • Target investors who match your stage and sector
  • Send thoughtful, customized meeting requests
  • Fill your calendar with high-value conversations

RESI Europe is structured to help early-stage companies connect efficiently with active investors. Through curated matchmaking and detailed attendee profiles, startups can prioritize fit over volume. Beyond pre-scheduled 1-to-1 meetings, the conference also creates opportunities for ad hoc introductions and follow-up discussions that often extend well beyond the event itself.

To help attendees prepare, Life Science Nation will host a dedicated RESI Europe Partnering Tutorial on Tuesday, March 3 at 10:00 AM Eastern Time (US and Canada). Understanding the RESI partnering system and using it to its maximum capabilities can make a significant difference in a company’s success at RESI Europe 2026. During this session, LSN staff will walk participants through how to navigate the platform, identify investors and strategic partners who are the best fit, manage outreach effectively, implement a strong follow-up strategy, and leverage the full range of conference content to strengthen their overall partnering experience. You can register for the webinar here.

Complimentary Second Attendee with 5-Day Registration

To help companies maximize their partnering coverage, RESI Europe 2026 is offering a complimentary second attendee pass with a standard 5-day registration.

Bringing a colleague allows your team to:

  • Cover more investor meetings
  • Attend concurrent sessions
  • Expand networking reach across the event
  • Ensure no key conversation is missed

This offer is not valid for Virtual or Audience Access passes. Attendees who registered for a 5-day ticket on or before February 22 may contact salescore@lifesciencenation.com to add a second attendee.

With partnering opening March 2 and expanded registration value now available, now is the time to secure your place. Enter the partnering system early, prepare strategically, and position your company to make the most of RESI Europe 2026.

Register for RESI Europe

Tags: , , , , , , , , , ,

RESI Europe and European VC Coalition Seek to Boost EU Biotech Investment 

24 Feb

By Sougato Das, President and COO, LSN

Sougato-Das

RESI Europe is one of the major pieces in the puzzle of how to stimulate biotech and life science investing in Europe. In addition to the largest investor partnering conference coming to Lisbon on March 23, the European Life Sciences Coalition (ELSC), a new alliance of major venture capital firms advocating for increased funding and policy support for Europe’s biotech sector, has launched. The coalition includes leading investors such as Novo Holdings, Sofinnova Partners, Forbion, and Omega Funds, representing a combined €24 billion in life sciences assets and involvement in more than 1,400 companies. It launched in association with Invest Europe, whose 650+ members manage 60% of European private equity and venture capital, totaling €1.25 trillion in assets. Alongside major initiatives like the European Innovation Council, whose funded companies enjoy 50% reimbursement for attending RESI Europe, the ELSC hopes to bring new energy to the entrepreneurial sector of life sciences. 

Despite Europe’s strong pharmaceutical presence—five of the world’s top 10 pharma companies by revenue are European—and the industry supporting 29 million EU jobs, the region struggles to scale and retain biotech and life science innovation. The coalition highlights several challenges: 

  • Fragmented capital markets 
  • Declining numbers of specialized VC firms 
  • Regulatory hurdles 
  • Limited access to growth capital 

Europe accounts for only 7% of global venture capital, compared to 63% for the U.S. and 14% for China. Fortunately, events like RESI Europe create a forum where nearly all of the firms representing the 7% are available for partnering, acting as a facilitator to stimulate European life science investment. The dire need for this is underscored by the fact that nearly all EU-based biotechs that went public last year chose to list outside the EU, highlighting concerns about capital flight. 

ELSC members joined the coalition to help reverse these trends, emphasizing the need for sustained funding from both public and private sources across all stages of life sciences development. Industry leaders argue that Europe must increase investment in innovative medicines and treatments, and create supportive policy frameworks and forums, like RESI Europe, or risk losing access to cutting-edge therapies. The ELSC aims to work with policymakers and leverage Invest Europe’s network to strengthen Europe’s ability to fund and scale biotech innovation domestically.

Register for RESI Europe

Tags: , , , , , , , , , , , , , , , , , , ,

Webinar to Fundraising Strategy: Preparing CEOs for RESI Europe and Beyond

24 Feb

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

As companies prepare for RESI Europe, preparation begins well before partnering opens. 

Life Science Nation is currently preparing private webinars for members of BioIndustry Park and members of the European Innovation Council. LSN is also available to schedule customized sessions for tech hubs, incubators, accelerators, and ecosystem partners interested in bringing this programming directly to their members. 

The following sessions are structured webinars designed to help early-stage CEOs strengthen the core components of capital formation. While particularly relevant ahead of RESI Europe, the insights apply to any early-stage founder preparing to engage investors. 

CEO Preparation Webinar Series 

LSN Event Partnering Process 

Thursday, January 29 | 10:00 AM ET
Watch the Recording

Attending partnering events plays a key role in fundraising success. This session outlines LSN’s structured approach to outreach strategy, investor targeting, follow-up discipline, and post-event conversion. 

Tips on Pitching 

Tuesday, February 10 | 10:00 AM ET
Watch the Recording

This workshop covers the full pitching lifecycle, from application strategy to live execution and navigating investor-led Q&A. Founders learn how to present risk, differentiation, and value in a way that supports underwriting decisions. 

Branding & Messaging Overview 

Thursday, February 26 | 10:00 AM ET
Sign Up

Founders learn how to align their tagline, elevator pitch, executive summary, tear sheet, and pitch deck so that messaging remains consistent across all investor touchpoints. Learn how to make your messaging stand out among the noise. 

RESI Europe Partnering Tutorial 

Tuesday, March 3 | 10:00 AM ET
Sign Up

A step-by-step walkthrough of the RESI partnering system, including filtering strategies, outreach management, and recommended follow-up processes to maximize conference ROI. 

Investor Webinar: Active Perspectives from Investors and Strategic Partners 

Tuesday, March 10 | 10:00 AM ET
Sign Up

Active investors and strategic partners discuss current capital deployment trends and how early-stage companies are being evaluated in today’s funding environment. 

European Webinar Focus 

From Discovery to Decision: Making Early-Stage Life Science Legible to Capital 

Sessions I–III are part of a dedicated European-focused webinar series designed specifically for companies navigating EU fundraising and cross-border capital engagement. These sessions examine structural translation challenges often faced by European early-stage ventures. 

Session I 

Why Solid Science Fails to Translate Before Capital Even Considers It
Watch the Recording

Explores how promising assets stall before diligence begins and why this is often a translation issue rather than a capital shortage. 

Session II 

Legibility, Signal, and the Real Work Between Seed and Series B
Tuesday, February 24 | 10:00 AM ET / 4:00 PM CET
Sign Up

Examines how signal is formed across scientific, regulatory, and commercial dimensions and what European and global investors require to underwrite risk. 

Session III 

Partnering Is Not Exposure. It Is Filtration
Wednesday, March 4 | 10:00 AM ET / 4:00 PM CET
Sign Up

Analyzes how different partnering environments align with different stages of company development and how founders can avoid engaging the wrong forum too early. 

Preparation as a Strategic Advantage 

Conferences accelerate capital formation. They do not replace preparation. 

The combined CEO Preparation and European-focused webinar tracks reinforce a consistent philosophy: investor engagement is a structured process built on messaging clarity, disciplined partnering, financial readiness, and an understanding of how capital evaluates risk. 

For founders attending RESI Europe, these webinars provide a direct framework for conference preparation. For founders fundraising more broadly, they offer durable guidance that applies well beyond a single event. 

Register for RESI Europe

Tags: , , , , , , ,

Confirmed Investors Attending RESI Europe 2026 — Early Bird Rates End Friday 

18 Feb

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to welcome investors from across the globe to RESI Europe 2026, taking place March 23 in Lisbon, Portugal, with virtual partnering scheduled for March 24–25 and 30–31. This premier event is designed to connect active early-stage investors with innovative life science companies and foster the partnerships that move promising science toward commercialization.

Early Bird rates expire this Friday, and those who register now will save €200. With partnering open March 2, this is the ideal time to secure your place and ensure access to the full RESI Europe experience.

RESI Europe convenes a highly engaged community of venture investors, corporate venture arms, family offices, strategic partners, and non-dilutive funding organizations, all actively evaluating new opportunities across therapeutics, diagnostics, medical devices, and digital health. The event is structured to maximize meaningful interactions, offering curated partnering, targeted networking, and direct visibility into emerging companies seeking capital and strategic collaboration.

For investors focused on sourcing new opportunities, building syndicates, and staying ahead of early-stage innovation trends, RESI Europe provides a concentrated and efficient environment to connect with founders, fellow investors, and ecosystem leaders from Europe, North America, and beyond. Conversations initiated at RESI frequently lead to follow-on diligence, partnerships, and investments that extend well beyond the event itself.

Confirmed RESI Europe Investors

Register before the Early Bird deadline this Friday to secure €200 in savings and confirm your participation alongside a growing global investor community.

Register for RESI Europe

Tags: , , , , , , , , , , , ,

RESI IPC Winner VerImmune Advances a New Immuno-Oncology Playbook  

18 Feb

VerImmune is an emerging biotechnology company advancing a novel virus-inspired platform designed to redirect the body’s existing immune memory toward hard-to-treat diseases. The company participated in RESI JPM as part of the Enterprise Singapore delegation, reflecting Singapore’s growing role as a global hub for biomedical innovation and cross-border collaboration. In this conversation, Founder & CEO Joshua Wang shares insights into VerImmune’s scientific approach, clinical ambitions, and momentum following recognition as an Innovator’s Pitch Challenge (IPC) winner. 

Joshua Wang
 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): For readers who are just discovering VerImmune, how do you describe the company and its scientific focus? 

Joshua Wang (JW): VerImmune is an IND-enabling stage biotechnology company leveraging the natural architecture of viruses to create a self-assembling Virus-inspired Particle (ViP™) platform for targeted therapeutic delivery of diverse payloads for oncology, autoimmunity, and animal health indications

VerImmune’s lead ViP program, VERI-101, is pioneering a new First-in-Class immuno-oncology paradigm that repurposes existing CMV-specific T-cell memory cells (present in ~85% of adults globally) to recognize and eliminate solid and metastatic tumors in a tumor-type-agnostic manner, either as a monotherapy or in combination with existing standards of care.

CD: What unmet medical need are you targeting, and how does your platform or approach differentiate you in the immunology landscape? 

JW: Despite recent blockbuster innovations like checkpoint inhibitors (PD-1/PD-L1) , antibody drug-conjugates and radioligand therapies, resistance to these treatments and other standards-of-care becomes inevitable and cancer recurs. This inevitably creates a large population of post-failure patients with limited to no options.
Hence, the biggest unmet need in oncology remains dealing with such cancer resistance and recurrence.

VerImmune has discovered that within these patient populations, regardless of previous treatment, most patients still retain a robust immunity to viruses.

VerImmune targets this preserved anti-viral immune memory and repurposes it against tumors, bypassing previous mechanisms of immune or genetic resistance.

Since all patients have pre-existing viral immunity (e.g to CMV which is what VERI-101 targets), VerImmune’ s approach represents a distinct and potentially category-defining modality in immuno-oncology, with clear strategic and partnering value in the post-failure setting and most importantly, giving patients one more shot at a treatment opportunity!

CD: What was your experience participating in the Innovator’s Pitch Challenge at RESI JPM? 

JW: As part of the Enterprise Singapore startup delegation from Singapore, participating at the Innovator’s Pitch Challenge at JPM RESI 2026 was a high-impact international opportunity as it occurred alongside 90+ other companies from around the world in a forum with concentrated investor and partner visibility. We were truly honored to win 2nd place which provides further external validation of our science, platform, and commercialization strategy before a global audience.

CD: With so many strong companies presenting, what feedback or reactions stood out to you from judges or attendees? 

JW: Despite a challenging biotech financing environment, which does not favor highly novel new mechanisms and approaches, we were encouraged that judges and attendees acknowledge the strategic logic that the post-PD1/ADC/RLT failure population still retains active anti-viral immunity. They highlighted the novelty of redirecting intact, non-exhausted viral immune memory rather than attempting to generate new anti-tumor immunity or introduce another small-molecule payload, viewing it as a differentiated and refreshing timely approach.

CD: How has RESI JPM helped advance investors, partners, or industry conversations for VerImmune? 

JW: Yes, being recognized as a winner has amplified the visibility of VerImmune’s approach and strengthened its perceived credibility. It has led to increased inbound interest from investors seeking to learn more, rather than relying primarily on outbound outreach.

CD: Where does the company currently stand in terms of funding, partnerships, or key development stages? 

JW: We are currently at the IND-enabling stage whereby we have already had a successful pre-IND meeting with the FDA which confirmed alignment on our planned GLP Toxicology studies and CMC manufacturing scale up to GMP clinical material. We are currently working to build up a syndicate to raise our Series A to close this financing which will advance our lead ViP program- VERI-101 into first-in-human clinical trials.

CD: What milestones or inflection points are most important for VerImmune in the coming months? 

JW: A key milestone is completing our Series A, which will enable full execution of our ongoing IND-enabling activities and transition VerImmune into a clinical-stage company with VERI-101 advancing into first-in-human studies.

The deadline to apply for the Innovator’s Pitch Challenge at RESI Europe has been extended to February 23. Applicants are encouraged to act quickly, as submissions are reviewed on a rolling basis.

Apply to Pitch at RESI Europe 2026

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Investor Fireside Chat in Barcelona: Building Momentum Toward RESI Europe  

10 Feb

By Brenda Olmos, Business Development Manager, Global Tech Hub and Sponsorship, LSN

In preparation for RESI Europe, the global life-science investment community will gather in Barcelona for an exclusive Investor Fireside Chat designed to equip founders and innovators with practical fundraising insights ahead of the conference.

Event Details
Date: February 18
Time: 15:00–19:00
Location: Hotel H10 Art Gallery, C/ Enric Granados 62, Barcelona

RSVP: https://form.jotform.com/260354367670157

This focused pre-RESI event brings together leading investors and pioneering entrepreneurs for an afternoon of strategy, storytelling, and networking within Barcelona’s vibrant innovation ecosystem.

Attendees will hear directly from investor Luis Pareras of InVivo Partners, joined by two standout founders shaping the future of neurotechnology and drug delivery: Ana Maiques of Neuroelectrics and Meritxell Teixidó of Gate2Brain. Together, they will share candid perspectives on what investors look for, how founders can position their companies effectively, and the realities of raising capital in today’s life-science landscape.

Speakers
Luis-Pareras Ana-Maiques Meritxell Teixidó
Luis ParerasFounder and Managing Partner
InVivo Partners		 Ana MaiquesCEO & CoFounder
Neuroelectrics		 Meritxell TeixidóCEO & CSO
Gate2Brain

The program will open with a hands-on Fundraising Bootcamp led by author and serial entrepreneur Dennis Ford (Boston), offering practical guidance on refining your pitch, navigating investor conversations, and building a compelling funding strategy. The session is designed to provide actionable takeaways that participants can immediately apply as they prepare for RESI Europe and beyond.

The afternoon will conclude with networking drinks, giving attendees the opportunity to connect with peers, investors, and ecosystem leaders in an informal setting.

Whether you are actively raising capital or planning your next financing round, this event offers a valuable opportunity to gain insight, build relationships, and align your strategy ahead of RESI Europe.

Register for RESI Europe

Tags: , , , , ,

Life Science Nation Names Dealflow.eu as a Title Sponsor of RESI Europe Lisbon; Highlights EIC Participation Pathway

10 Feb

By Greg Mannix, VP, EMEA Business Development, LSN

New collaboration strengthens access for European life science innovators to engage global capital investors and licensing partners

Cambridge, MA and Lisbon, Portugal 

Life Science Nation (LSN) announced today a partnership with Dealflow.eu, naming the organization as a Title Sponsor of RESI Europe Lisbon. The collaboration supports the identification and preparation of high-potential European life science innovators and strengthens pathways for companies—where eligible—to leverage European Innovation Council (EIC) reimbursement mechanisms to participate in the RESI partnering ecosystem.

Dealflow.eu operates as a European innovation matchmaking and readiness platform, surfacing high-potential life sciences and deep-tech companies and supporting their engagement with global investors and strategic partners. Through this collaboration, Dealflow.eu will route a curated cohort of life science companies to RESI Europe Lisbon, positioning them in front of a global audience of investors and partners actively seeking early-stage opportunities.

RESI Europe Lisbon serves as the global activation layer of the Life Science Nation partnering ecosystem, connecting emerging technologies with investors and strategic partners through curated matchmaking, investor panels, and the Innovator’s Pitch Challenge. Unlike broad innovation showcases, RESI is purpose-built for early-stage life sciences partnering and capital formation, enabling qualified investors and partners to engage with technologies prepared for global scrutiny.

As part of this collaboration, Dealflow.eu will support eligible companies in accessing available reimbursement mechanisms—such as those offered through EIC programs, where applicable—to offset a portion of RESI Europe registration costs. This helps reduce participation barriers and expands access for promising European life sciences innovators to connect with global capital and strategic partner networks.

“This partnership strengthens the pathway from early innovation to global partnering,” said Dennis Ford, Founder and CEO of Life Science Nation. “Dealflow.eu operates upstream, identifying and preparing high-potential innovators for investor engagement. RESI operates downstream, providing the global activation environment where capital investors and strategic partners connect with emerging technologies. At the same time, programs such as those offered through the EIC can help support company participation and readiness along that journey.”

“We see RESI Europe as a highly complementary activation platform for the Dealflow.eu network,” said André Moraes Sarmento, Dealflow.eu. “Our mission is to connect high-potential innovators with investors, corporates, and strategic partners. This collaboration gives life science companies direct access to a global audience of qualified investors and licensing partners actively seeking early-stage technologies.”

The collaboration also includes coordinated programming at RESI Europe Lisbon, dedicated visibility opportunities for participating innovators, pre-conference preparation support, and continued alignment to strengthen pathways from European innovation to global market engagement.

RESI Europe Lisbon will take place in Lisbon, Portugal, bringing together global investors, strategic partners, and early-stage life sciences innovators across therapeutics, devices, diagnostics, digital health, and enabling technologies.

About Life Science Nation

Life Science Nation operates a global partnering and matching ecosystem that connects early-stage life sciences companies with qualified capital investors and licensing partners worldwide. Its platforms include the RESI Conference Series, LSN Labs entrepreneurial education and readiness programs, and global partnering campaign infrastructure.

About Dealflow.eu

Dealflow.eu is a European innovation matchmaking and readiness platform connecting high-potential innovators with investors, corporates, and strategic partners across Europe and globally.

Media Contact
Caitlin Dolegowski
Marketing Manager
Life Science Nation
c.dolegowski@lifesciencenatio.com
719-229-9290

Tags: , , , , , , , , , ,

← Older Entries